Articles

Impact of FDA Turnover on Rare Disease Drug Development

Biotech executives and academic experts discuss the implications of FDA turnover on rare disease drug development, highlighting investment risks and opportunities.

Fetal Gene Therapy: Breaking the Taboo on Embryo Editing

This article examines the recent progress in fetal gene therapy and its implications for the ethical considerations surrounding embryo editing.

Amgen's CFO Transition: Implications for Pharma Investments

Amgen bids farewell to its CFO and attracts a Galderma executive with a significant bonus. This article explores the implications for the pharma industry.

Gilead's $140M Deal with Yuhan: What It Means for Pharma

Gilead Sciences has signed a significant $140M deal with Yuhan, a Korean API manufacturer. This article explores the implications for the pharmaceutical landscape.

Parabilis Pursues IPO After $800M Funding for Undruggable Targets

Parabilis has raised $800M and is now seeking an IPO to tackle previously undruggable targets, marking a significant shift in its strategy.

Oorja Launches New Fibrosis Drugs: Insights for Pharma Teams

Oorja, founded by Acceleron veterans, aims to innovate fibrosis treatments. This article explores the implications for the pharmaceutical industry.

Tracking Cellular Disruptions in Type 1 Diabetes: Insights for Pharma

This article explores recent findings on cellular disruptions linked to type 1 diabetes and their implications for pharmaceutical development and investment.

Bristol Myers Expands AI Capabilities with Anthropic Partnership

Bristol Myers has deepened its investment in artificial intelligence by partnering with Anthropic. This strategic move aims to enhance its drug development capabilities and competitive edge.

How GLP-1s are Transforming Pharma's Consumer Relationships

This article examines the evolving relationship between pharmaceutical companies and consumers, driven by the rise of GLP-1 medications.

Ebola: A Dual Perspective from Doctor and Patient

This article provides a unique perspective on Ebola from both a healthcare provider and a patient, emphasizing the importance of global awareness and support.

ImmunityBio's Anktiva Expansion: FDA Decision Date Insights

ImmunityBio has secured a decision date from the FDA regarding Anktiva's expansion. This article explores the implications for pharma stakeholders.

BeOne Launches ‘One Save Changes Everything’ Campaign with Tim Howard

BeOne has launched a new campaign featuring Tim Howard, aiming to reshape perceptions in the pharmaceutical sector. This article explores the implications for B2B stakeholders.

Kennedy's Leadership Shakeup: Implications for Preventive Services

Kennedy's recent decision to fire two leaders from the preventive services task force raises questions about future strategies and impacts on the pharmaceutical industry.

Ipsen's Transition Challenges: Insights for Pharma Teams

Ipsen highlights the challenges faced by teens transitioning to adult care. This article explores the implications for pharmaceutical teams and stakeholders.

Tarsus Partners with John Cena for Demodex Blepharitis Campaign

Tarsus has launched a new campaign featuring John Cena to raise awareness about Demodex blepharitis. This article explores the implications for the pharmaceutical industry.

Paragon's Reverse Merger: Implications for Migraine Drug Development

Paragon's latest reverse merger signals a strategic shift in migraine drug development. This article explores its implications for the pharmaceutical industry.

BBSW AI Solution: Key Insights from the 2026 Event

The BBSW AI Solution event in Foster, USA, promises to unveil critical advancements in AI technology for the pharma industry. Stay tuned for live updates and key takeaways.

Pharma Manufacturing World 2026: Key Insights and Expectations

As Pharma Manufacturing World 2026 approaches, key insights and expectations are emerging. This article previews the event's agenda, key players, and potential catalysts.

Regulatory Education for 2026: Key Insights Ahead of the Event

As we approach the Regulatory Education event in May 2026, industry professionals are eager to understand the implications for regulatory strategies. This article outlines key takeaways and what to expect from the event.

Atara Bounces Back with FDA Approval in Oncology

Atara has received FDA approval for its oncology treatment, marking a significant turnaround for the company. This article analyzes the implications for investors and BD teams.